Sysmex Corp is primarily active in the healthcare and medical technology industries.

The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).

Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.

Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.

Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.

Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.

Analysts currently set an average price target of 2391,26 JPY for the Sysmex stock (median: 2320,50 JPY), implying +21,1 % versus the latest price. The consensus is based on 21 analyst ratings.

Sysmex Analüütikute kurssizihtpunktid 2026

21 analysts currently rate the Sysmex stock: 16 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sysmex to generate revenue of 498,17 B JPY and earnings per share of 64,06 JPY.

Sysmex Analüütikute kurssizihtpunktid 2026

Converted at the current exchange rate, the Sysmex share trades at 10,64 EUR (1975,00 JPY).

The Sysmex share (6869.T) is listed on 4 stock exchanges, including: Frankfurt (0YX.F), München (0YX.MU).

Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.

oodatav Sysmex käive on 498,17 B JPY. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

oodatav Sysmex kasum on 39,94 B JPY. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Sysmex jaoks on praegu 30,83. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Sysmex aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Sysmex jaoks on praegu 2,47. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Sysmex aktsia jaoks.

Eulpooli kvaliteedinäitaja Sysmex jaoks on 8/10.

Sysmex ISIN on JP3351100007. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Sysmex WKN on 897966. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Sysmex ticker on 6869.T. Ticker-sümbol kasutatakse Sysmex aktsiate kauplemiseks börsil.

Viimase 12 kuu jooksul maksis Sysmex dividendi summas 35,00 JPY . See vastab dividendisisestusele umbes 1,77 %. Järgmise 12 kuu jooksul eeldatakse, et Sysmex maksab dividendi 64,92 JPY.

Sysmex dividendide tootlus on praegu 1,77 %.

Sysmex maksab dividendi, mis jagatakse välja kuudel , , , .

Sysmex maksis dividende igal aastal viimase 30 aasta jooksul.

Järgmistel 12 kuul eeldatakse dividende summas 64,92 JPY. See vastab dividendisisestusele 3,29 %.

Sysmex kuulub sektorisse 'Tervishoid'.

Viimase dividendi saamiseks Sysmex poolt kuupäevast summas 18 JPY pidi sul aktsia portfellis olema enne ex-kuupäeva .

Viimane dividend maksti välja .

Aastal 2025 jagas Sysmex dividendidena välja 28 JPY.

Sysmex dividendid jagatakse välja valuutas JPY.